Citations

Showing 10 of 108162 citations.

Antistaphylococcal Penicillin vs Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Spinal Epidural Abscesses
Campioli, Cristina Corsini , Go, John Raymond , Saleh, Omar Abu , Yetmar, Zachary A. , Osmon, Douglas R. , Corsini Campioli, Cristina , Abu Saleh, Omar , Yetmar, Zachary A , Osmon, Douglas R , Go, J Raymond , Challener, Douglas W.

Mayo Clinic

Open Forum Infectious Diseases | February 16, 2021 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/ofid/ofab071 | PMID 33738321 Get It

Abstract Cefazolin is commonly used as an alternative to antistaphylococcal penicillins (ASPs) in treating methicillin-susceptible Staphylococcus aureus (MSSA) infections; however, no study has compared these agents in MSSA spinal epidural abscess (SEA). We describe our experience in managing MSSA SEA and compare the clinical efficacy of cefazolin with ASPs. This retrospective multicenter study reviewed 79 adult patients diagnosed with SEA between January 2006 and July 2020 using data collected from electronic health records and clinical microbiology laboratory databases. Forty-five patients received cefazolin, while 34 received ASPs. The total antibiotic duration was longer in the ASPs group but not statistically significant. There were no significant differences in treatment failure at week 6 vs week 12, 30-day vs overall mortality, or in 90-day recurrence rates between the treatment groups. Cefazolin was equally as effective as ASPs, and our findings suggest that it can be an alternative to ASPs in the treatment of MSSA SEA.
Education as Culture: The Amazing and Awesome Case Conference
Purdy, Eve , Roseby, Rob, B., Manuela Brinkmann , Blackmore, Elizabeth, Cabrera, Daniel , Cabrera, Daniel , Meyer, Chris

Mayo Clinic

Journal of Graduate Medical Education | February 15, 2021 | Volume: 13 | Issue: 1 | Pages: 18-21

10.4300/jgme-d-20-00407.1 | PMID 33680294 Get It

Hypomania associated with high dose ketamine treatment
Hu, Yuliang , Kung, Simon , Özerdem, Ayşegül , Voort, Jennifer L. Vande , Singh, Balwinder , McDonald, William M. , Riva‐Posse, Patricio , Frye, Mark A. , Vande Voort, Jennifer L., Singh, Balwinder , Ozerdem, Aysegul

Mayo Clinic

Bipolar Disorders | February 15, 2021 | Volume: 23 | Issue: 4 | Pages: 426-428

10.1111/bdi.13059 | PMID 33587793 Get It

Faculty Opinions recommendation of COVID-19 Myocardial Pathology Evaluated Through scrEening Cardiac Magnetic Resonance (COMPETE CMR).
Gersh, Bernard J.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.738658985.793582810 Get It

Blood Biomarkers of Intestinal Epithelium Damage Regenerating Islet‐derived Protein 3α and Trefoil Factor 3 Are Persistently Elevated in Patients with Alcoholic Hepatitis
Yang, Jing , Syed, Fahim, Xia, Ying , Shah, Vijay H. , Chalasani, Naga , Zheng, Xiaoqun , Yu, Qigui , Lou, Yongliang , Li, Wei , Li, Wei , Sanyal, Arun J.

Mayo Clinic

Alcoholism: Clinical and Experimental Research | February 15, 2021 | Volume: 45 | Issue: 4 | Pages: 720-731

10.1111/acer.14579 | PMID 33587293 Get It

BackgroundHeavy alcohol consumption disrupts gut epithelial integrity, leading to increased permeability of the gastrointestinal tract and subsequent translocation of microbes. Regenerating islet‐derived protein 3α (REG3α) and Trefoil factor 3 (TFF3) are mainly secreted to the gut lumen by Paneth and Goblet cells, respectively, and are functionally linked to gut barrier integrity. Circulating levels of REG3α and TFF3 have been identified as biomarkers for gut damage in several human diseases. We examined whether plasma levels of REG3α and TFF3 were dysregulated and correlated with conventional markers of microbial translocation (MT) and pro‐inflammatory mediators in heavy drinkers with and without alcoholic hepatitis (AH).MethodsCross‐sectional and longitudinal studies were performed to monitor plasma levels of REG3α and TFF3 in 79 AH patients, 66 heavy drinkers without liver disease (HDC), and 46 healthy controls (HC) at enrollment and at 6‐ and 12‐month follow‐ups. Spearman correlation was used to measure the relationships of REG3α and TFF3 levels with MT, disease severity, inflammation, and effects of abstinence from alcohol.ResultsAt enrollment, AH patients had significantly higher levels of REG3α and TFF3 than HDC and HC. The elevated REG3α levels were positively correlated with the 30‐day fatality rate. Plasma levels of REG3α and TFF3 in AH patients differentially correlated with conventional MT markers (sCD14, sCD163, and LBP) and several highly up‐regulated inflammatory cytokines/chemokines/growth factors. At follow‐ups, although REG3α and TFF3 levels were decreased in AH patients with alcohol abstinence, they did not fully return to baseline levels.ConclusionsCirculating levels of REG3α and TFF3 were highly elevated in AH patients and differentially correlated with AH disease severity, MT, and inflammation, thereby serving as potential biomarkers of MT and gut epithelial damage in AH patients.
Machine Learning Analysis of Volatolomic Profiles in Breath Can Identify Non-invasive Biomarkers of Liver Disease
Thomas, Jonathan , Roopkumar, Joanna, Patel, Tushar

Mayo Clinic

No container title available | February 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-192281/v1 Get It

Abstract Disease-related effects on hepatic metabolism can alter the composition of chemicals in the circulation and subsequently in breath. The presence of disease related alterations in exhaled volatile organic compounds (VOC) could provide a basis for non-invasive biomarkers of hepatic disease. This study examined the feasibility of combining global VOC (volatolomic) profiles from breath analysis and machine learning to develop signature pattern-based biomarkers for cirrhosis. Breath samples were analyzed using thermal desorption-gas chromatography-field asymmetric ion mobility spectroscopy to generate volatolomic profiles. Samples were collected from 35 persons with cirrhosis, 4 with non-cirrhotic portal hypertension, and 11 healthy participants. Molecular features of interest were identified to determine their ability to classify cirrhosis or portal hypertension. A molecular feature score was derived that increased with the stage of cirrhosis and had an AUC of 0.78 for detection. Chromatographic breath profiles were utilized to generate machine learning-based classifiers. Algorithmic models could discriminate presence or stage of cirrhosis with a sensitivity of 88-92% and specificity of 75%. These results demonstrate the feasibility of volatolomic profiling to classify clinical phenotypes without identifying specific compounds. These studies will pave the way in developing non-invasive biomarkers of liver disease based on volatolomic signatures found in breath.
Abstract SS2-01: Impact of the COVID-19 pandemic on the multidisciplinary management of breast cancer: Initial analysis of the american society of breast surgeons mastery COVID-19 registry
Nguyen, Toan T. , Yang, Qiuyu , Wagner, Kathryn A , Brown, Eric, Dietz, Jill R. , Wilke, Lee G. , Hanlon, Bret M. , Strickland, Pamela, Boughey, Judy C.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: SS2-01-SS2-01

10.1158/1538-7445.sabcs20-ss2-01 Get It

Abstract Background: The COVID-19 pandemic rapidly altered health care worldwide. To save protective equipment and minimize exposures, many hospitals stopped some or all cancer surgery, leading oncologic providers to quickly adjust patient management. The goal of this study is to describe the breast cancer patient level changes which occurred during the initial months of COVID-19 in the United States. Methods: The American Society of Breast Surgeons developed a COVID-19 specific registry, within the established HIPPA compliant Mastery of Breast Surgery Program. Surgeons entered patient demographic data as well as their surgical and medical care (Neoadjuvant endocrine (NET) vs Neoadjuvant chemotherapy (NCT)). Data fields tracked whether decisions were usual for that practice, or modified due to COVID-19. Results: Between 3/1 and 6/17/2020, data from 1781 patients was entered by 154 surgeons. Mean age was 63, 78% Caucasian, 10% African American, 6% Hispanic; with geographic distribution ranging from 10.8% Northwest to 29.5% Northeast. Initial consultation took place in-person for 94.8% and only 5.2% (89) occurred via video/telephone. To date, just over 1% (14) of patients tested positive for COVID-19. Mean invasive tumor size was 21.2mm and 15.7% were node positive. Of 1445 invasive breast cancers 75% (1081) were ER +/HER2-, 13.5% (195) HER2+, 11.1% (160) triple negative (TNBC) (9/missing data). DCIS comprised 18.2% (325) of the cohort. Of 267 cases of ER+ DCIS, 49% (131) had primary surgery and 49% (130) received NET. The majority of NET use was due to COVID-19, 95% (124). Almost all (50/52) ER- DCIS underwent primary surgery (6/missing ER). Table 1 describes the management for the 1436 patients with invasive cancer with known biomarkers. NET due to COVID-19 was utilized in 45% (482), with only 5% (54) as part of usual practice. Increasing age was not a statistically significant factor in the use of NET (OR 0.99, 95% CI 0.97-1.01). In comparison to patients from the Northwest, patients from the Southwest and Northeast had the greatest use of NET(COVID-19) vs NET(usual) (ORs 14.4 and 4.6) Genomic assay testing was performed on the core biopsy in 216 patients, with 65% (141) due to COVID-19. Among the patients who had genomic testing due to COVID-19, 116 (82%) had NET, 18 (13%) had NCT, with the remaining having primary surgery. Of 472 patients treated with primary surgery for which the impact of COVID-19 was provided, surgery was delayed in 20% (96). Patients from the Northeast had a 2.1 x greater odds of having surgery delayed in comparison to those from the Midwest. Patients also experienced changes to their surgical plan with the most common changes being 6% (27) converting from mastectomy to breast conservation and 7% (34) from mastectomy with reconstruction to mastectomy without reconstruction. Conclusion: COVID-19 led to significant modifications in breast cancer treatment, including high rates of NET, genomic assay testing on core biopsies as well as delays in surgery; each of which were consistent with the prioritization and treatment recommendations from the COVID-19 Pandemic Breast Cancer Consortium. The majority of patients with TNBC and HER2+ disease received guideline concordant NCT. The ASBrS Mastery COVID-19 registry provides a snapshot into the rapid care changes caused by the pandemic, has ongoing data entry and analysis and will enable understanding of the impact on long term breast cancer outcomes. Table 1: Biomarker specific treatmentsER+/HER2- (1081)TNBC (160)HER2+/any ER (195)Mean Age656159African American (%)97(9%)21(13%)27(14%)Primary Surgery (usual)386 (36%)50 (31%)37 (19%)Primary Surgery (COVID-19)28 (2.6%)6 (3.7%)6 (3.1%)NET (usual)54 (5%)NA1(0.5%)NET (COVID-19)482 (45%)NA6 (3.6%)NCT (usual)90 (8.3%)98 (61%)137 (70%)NCT (COVID-19)39 (3.6%)6 (3.7%)8 (4.1%) Citation Format: Lee Gravatt Wilke, Toan T Nguyen, Qiuyu Yang, Bret M Hanlon, Kathryn A Wagner, Pamela Strickland, Eric A Brown, Jill Dietz, Judy C Boughey. Impact of the COVID-19 pandemic on the multidisciplinary management of breast cancer: Initial analysis of the american society of breast surgeons mastery COVID-19 registry [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SS2-01.
Abstract SP094: DCIS - Con
McLaughlin, Sarah L. , McLaughlin, S

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: SP094-SP094

10.1158/1538-7445.sabcs20-sp94 Get It

Abstract Ductal carcinoma in situ (DCIS) represents a collection of biologically heterogenous pre-invasive breast lesions some with the potential for progression to invasive cancer. Widespread adoption of screening mammography has increased the diagnosis of DCIS and may contribute to overdiagnosis identifying some conditions that may never impact one’s overall health. Unfortunately, clinicians treating DCIS patients currently lack robust biomarkers stratifying DCIS patients into those at high or low risk for invasive progression. Further, variations in pathologic assessment and grade, intra-lesional DCIS heterogeneity, and discordance in pathologic interpretations between pathologists make it challenging for providers to further identify appropriate low risk DCIS patients for active surveillance. Guideline concordant care including excision and potentially radiation and anti-estrogen therapies should remain as the standard of care and provides a definitive treatment endpoint which patients desire. Existing evidence documents a significant upstage rate of DCIS to invasive disease at surgical excision including a small, but important population benefiting from adjuvant systemic therapy. Finally, patient anxiety and documented poor adherence rates to endocrine therapy preclude active surveillance and after all the morbidity of surgical excision is low. Citation Format: S McLaughlin. DCIS - Con [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP094.
Abstract SP133: Oncofertility
Ruddy, Kathryn J.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: SP133-SP133

10.1158/1538-7445.sabcs20-sp133 Get It

Abstract Many young women have not completed their desired childbearing when they are diagnosed with breast cancer. This is increasingly true as the average age of first birth rises such that more premenopausal breast cancers are diagnosed in nulliparous women. Even women who already have one or more children at the time of their cancer diagnosis may be hoping to become pregnant again. Because chemotherapy is gonadotoxic and endocrine therapy is contraindicated during pregnancy(allowing natural ovarian aging over the 5-10 years of adjuvant therapy recommended for those with endocrine-sensitive stage 1-3 tumors), breast cancer treatments can impair fertility. Fertility preservation strategies including oocyte cryopreservation and embryo cryopreservation should be considered prior to initiation of systemic therapy for young women with fertility concerns, often using modified ovarian stimulation protocols to minimize delays in cancer treatment. The administration of a gonadotropin-releasing hormone agonist before and during chemotherapy to help maintain ovarian function is more controversial, but can also be considered. It is critical that we offer reproductive counseling and access to fertility preservation techniques at the time of diagnosis, and that we also continue to discuss contraception and fertility planning during and after cancer treatment. Results from the POSITIVE trial, which is assessing pregnancy and cancer outcomes of young women who wished to take a break from adjuvant endocrine therapy to attempt conception, are eagerly awaited to inform these discussions. This talk will address current knowns and unknowns related to the optimal management of reproductive concerns in premenopausal women with breast cancer. Citation Format: K Ruddy. Oncofertility [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP133.
Abstract PS9-46: Pre-diagnosis major life stressors and breast cancer outcomes
Pai, Tanmayi , Vallow, Laura A., Seneviratne, Danushka S. , Mussallem, Dawn M. , Cornell, Lauren , Cornell, Lauren F

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PS9-46-PS9-46

10.1158/1538-7445.sabcs20-ps9-46 Get It

Abstract Background: Multiple studies have identified an association between diagnosis of breast cancer and post-diagnosis psychological distress. Some have taken a step further, identifying predictive markers of distress in diagnosed patients and interventions to minimize post-diagnosis distress. Data regarding pre-diagnosis psychological distress and its impact on surgical decision making and clinical outcomes in the breast cancer population are limited. Here, we assessed pre-diagnosis major life stressors and breast cancer outcomes in a single-center population. Methods: Patients with newly diagnosed stage 0-3 breast cancer seen at Mayo Clinic Florida between June 11, 2018, and October 7, 2019, were included. Prior to their initial visit, patients were administered a voluntary telephone survey regarding the incidence of major life events and stressors during the 18 months preceding their diagnosis. Demographic data including age and ethnicity were also included. Subsequent clinical outcomes were obtained through retrospective chart review. Clinical outcomes were assessed with descriptive statistics. Chi-square tests were used to compare subgroups, with p < 0.05 considered statistically significant. Results: Of 469 patients seen for a new breast cancer diagnosis, 222 patients completed the intake survey and met inclusion criteria. Median age was 60 (27-84) years. 80.6% of patients were white, 7.7% were black, 5.4% were Asian/Pacific Islander, and 2.3% were Latino. Over 95% endorsed having some form of social support. 51.3% reported experiencing a major life event prior to breast cancer diagnosis. Of these patients (n = 114), 43.9% denoted this stressor as family-related, as compared to 20.2% citing non-breast cancer illness, 14.9% claiming relationship stress, and 14% describing employment-related stress. Only 1.8% endorsed stress caused by financial concerns. Multiple major life events were reported by 10.8% of all included patients. Subgroup analysis of the patients with pre-diagnosis stress revealed a similar demographic distribution to the overall sample. Compared to the subgroup without pre-diagnosis stress (n = 108), there were more patients with carcinoma in situ and stage T3/T4 disease (21.1% versus 13.0%, p = 0.11) and 11.4% versus 10.2%, p = 0.77), respectively) in the subgroup with pre-diagnosis stress, although these differences were not statistically significant. More patients with pre-diagnosis stress elected to undergo mastectomy (34.2% versus 22.2%, p = 0.048) as compared to the group without stress. Conclusions: With over half of sample patients reporting pre-diagnosis major life stressors, psychological distress is prevalent prior to breast cancer diagnosis and should be considered as a factor for early intervention, such as psychological and financial counseling, during breast cancer evaluation. The sample population was predominantly white and resource-rich in terms of financial and social support, highlighting a need for characterization of pre-diagnosis psychological distress in more ethnically diverse and/or resource-limited settings. Although additional study is recommended, current data suggest possible associations between pre-diagnosis psychological distress and treatment decision making, particularly the decision to pursue mastectomy. Citation Format: Tanmayi Pai, Laura Vallow, Danushka Seneviratne, Dawn Mussallem, Lauren Cornell. Pre-diagnosis major life stressors and breast cancer outcomes [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-46.